LON:LABS Life Science REIT (LABS) Share Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free LABS Stock Alerts GBX 37.50 -0.30 (-0.79%) (As of 03:31 PM ET) Add Share Share Today's Range 37.40▼ 3850-Day Range 37.10▼ 44.3052-Week Range 37.10▼ 77.40Volume736,580 shsAverage Volume959,016 shsMarket Capitalization£131.25 millionP/E RatioN/ADividend Yield10.67%Price TargetGBX 79 Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendStock AnalysisAnalyst ForecastsChartDividend Get Life Science REIT alerts: Email Address Life Science REIT MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.9% UpsideGBX 79 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 stars 3.5 Analyst's Opinion Consensus RatingLife Science REIT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLife Science REIT has received no research coverage in the past 90 days.Read more about Life Science REIT's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for LABS. Previous Next 1.7 Dividend Strength Dividend LeadershipLife Science REIT is a leading dividend payer. It pays a dividend yield of 7.09%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthLife Science REIT does not have a long track record of dividend growth.Read more about Life Science REIT's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LABS. Previous Next 0.6 News and Social Media Coverage Search Interest3 people have searched for LABS on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Life Science REIT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.04% of the stock of Life Science REIT is held by insiders.Percentage Held by Institutions74.04% of the stock of Life Science REIT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Life Science REIT's insider trading history. Previous Next 0.7 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Life Science REIT is -475.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLife Science REIT has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About Life Science REITRead More LABS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LABS Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive LABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Life Science REIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/13 Dividend4/04/2024Dividend Payable5/13/2024Today5/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorN/A Industry N/A Sub-IndustryN/A Current SymbolLON:LABS CUSIPN/A CIKN/A Webwww.lifesciencereit.co.uk PhoneN/AFaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price TargetGBX 79 High Stock Price TargetGBX 79 Low Stock Price TargetGBX 79 Potential Upside/Downside+107.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-29,190,000.00 Net Margins-151.24% Pretax MarginN/A Return on Equity-8.24% Return on Assets0.82% Debt Debt-to-Equity Ratio31.91 Current Ratio1.35 Quick RatioN/A Sales & Book Value Annual Sales£19.30 million Price / Sales6.89 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 90 per share Price / Book0.42Miscellaneous Outstanding Shares350,000,000Free FloatN/AMarket Cap£133 million OptionableNot Optionable Beta0.20 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Sally Ann Forsyth O.B.E.Ph.D., Independent Non-Exec. Director & Sustainability LeadMr. Simon Farnsworth (Age 56)Managing Director of Ironstone Asset Management Limited Mr. David LewisDirector of Operations & Fin. of Ironstone Asset Management LimitedMs. Joanna WaddinghamHead of Investor Relations & Corp. Affairs of Ironstone Asset Management LimitedMs. Stephanie AdamsLegal Counsel of Ironstone Asset Management LimitedMr. Ian HarrisDirector of Asset Management of Ironstone Asset Management LimitedMs. Pippa StaceyHead of ESG & Consultant of Ironstone Asset Management LimitedTamara DeeringHead of Financial Planning & Reporting of Ironstone Asset Management LimitedMr. Daniel WilliamsCorp. & Devel. Financial Controller - Ironstone Asset Management LimitedMore Executives LABS Stock Analysis - Frequently Asked Questions Should I buy or sell Life Science REIT stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Life Science REIT in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LABS shares. View LABS analyst ratings or view top-rated stocks. What is Life Science REIT's stock price target for 2024? 1 brokers have issued 1 year price targets for Life Science REIT's shares. Their LABS share price targets range from GBX 79 to GBX 79. On average, they expect the company's share price to reach GBX 79 in the next twelve months. This suggests a possible upside of 107.9% from the stock's current price. View analysts price targets for LABS or view top-rated stocks among Wall Street analysts. How have LABS shares performed in 2024? Life Science REIT's stock was trading at GBX 63.20 at the beginning of 2024. Since then, LABS shares have decreased by 39.9% and is now trading at GBX 38. View the best growth stocks for 2024 here. How often does Life Science REIT pay dividends? What is the dividend yield for Life Science REIT? Life Science REIT declared a dividend on Tuesday, March 26th. Shareholders of record on Thursday, April 4th will be given a dividend of GBX 1 per share on Monday, May 13th. This represents a dividend yield of 2.32%. The ex-dividend date is Thursday, April 4th. The official announcement can be seen at this link. Read our dividend analysis for LABS. Is Life Science REIT a good dividend stock? Life Science REIT (LON:LABS) pays an annual dividend of GBX 4 per share and currently has a dividend yield of 7.09%. LABS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for LABS. How do I buy shares of Life Science REIT? Shares of LABS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:LABS) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDems have chosen Biden replacement?Paradigm PressDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsHow Biden has already won 2024Porter & CompanyUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate CapitalMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Life Science REIT plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
